Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS-SLE 1: phase III ianalumab regimens plus standard therapy in systemic lupus erythematosus
CTR20230037Phase 3Active
- Sponsor
- Novartis
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ianalumab in systemic lupus erythematosus (SLE), sponsored by Novartis. Started Mar 2023; status: active.
02
Drugs
ianalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20230037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230037.